Stay updated on Amivantamab & Lazertinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib in NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe webpage has been updated to include the term 'Metastatic Non Small Cell Lung Cancer' and the version has been revised to v2.15.0. Additionally, the name of the principal investigator has been removed, while the collaborators remain the same.SummaryDifference50%
- Check19 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 13, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.3%
- Check27 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check63 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
- Check70 days agoChange DetectedThe webpage has updated its date references, removing some past dates and adding new future dates. This indicates a shift in the timeline of events or availability.SummaryDifference0.4%
- Check77 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1.0%
Stay in the know with updates to Amivantamab & Lazertinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.